Glycopyrrolate (Glycopyrronium Bromide)

06/06/2018 - "Conclusions: The drug/device combination of glycopyrrolate/eFlow CS significantly improved HRQoL, as measured by the SGRQ, offering a potential maintenance treatment option in patients with moderate to very severe COPD. "
01/01/2012 - "Once-daily inhaled glycopyrronium bromide has characteristics important for use in COPD, including a fast onset of action, sustained 24-hour bronchodilatation, and improvement in exercise tolerance, and therefore appears to have the potential for a significant role in the future management of COPD."
03/28/2016 - "Health status (SGRQ total score and COPD assessment test), rescue medication use and daily total COPD symptom scores were significantly improved with glycopyrrolate versus placebo over 12 weeks. "
03/28/2016 - "Twice-daily glycopyrrolate 15.6 μg showed statistically significant and clinically meaningful improvements compared with placebo in lung function, COPD symptoms, health status, and rescue medication usage in COPD patients with moderate-to-severe airflow limitation. "
01/01/2021 - "Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies."

04/01/2017 - "Glycopyrrolate 1 mg was not superior to placebo, whereas 2 mg showed a significant clinical improvement of nocturnal sialorrhea compared with placebo. "
05/01/2011 - "Glycopyrrolate, however, demonstrated significant reduction of hypersalivation in a randomized controlled trial. "
08/01/1998 - "Glycopyrrolate was used by 37 of 41 respondents, with significant improvement in drooling noted in the vast majority (95%) of cases as indicated by a five-point rating scale. "
11/06/2021 - "This study demonstrates the efficacy of a compounded glycopyrrolate syrup on drooling severity, frequency and ensures a better QoL in patients and their caregivers."
08/01/2014 - "CIS continued in the patient described in case 4 despite treatment with glycopyrrolate, with only mild improvement in the severity and frequency of drooling. "

05/01/2022 - "Glycopyrronium cloth can be used successfully to treat palmar hyperhidrosis. "
11/01/2004 - "We conclude that glycopyrrolate iontophoresis is more effective than tap water iontophoresis in the treatment of palmoplantar hyperhidrosis and that glycopyrrolate iontophoresis has both local and systemic effects on perspiration."
01/01/2013 - "Glycopyrrolate is an effective medication in the treatment of compensatory hyperhidrosis that, can alleviate anxiety and improve patients' quality of life."
09/01/2012 - "Iontophoresis using glycopyrronium bromide is an effective and well-tolerated treatment for primary palmar hyperhidrosis. "
07/01/2002 - "We conclude that topical glycopyrrolate is effective in treating craniofacial hyperhidrosis and is associated with few adverse effects."

04/29/2020 - "Health-Related Effects of Home Nebulization With Glycopyrronium on Difficult-to-Treat Asthma: Post-Hoc Analyses of an Observational Study."
10/01/2005 - "Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma."
07/01/1992 - "Glycopyrrolate for asthma."
01/01/1987 - "Glycopyrrolate may be a useful long-acting drug for the treatment of asthma."
01/01/1987 - "Prolonged effect of inhaled glycopyrrolate in asthma."

10/01/1986 - "With the administration of glycopyrrolate, the bradycardia was minimized, but cardiac performance was not improved. "
01/01/2018 - "The maximal HR achieved in the glycopyrrolate group was significantly higher compared to controls (MD, 15.85 bpm [5.40-26.31]; P < .0001); however, the incidence of bradycardia was not statistically different. "
08/01/2017 - "Additional episodes of bradycardia intraoperatively were responsive to glycopyrrolate. "
07/01/2014 - "The episodes of bradycardia did not coincide with orotracheal manipulation, were not prevented by escalating doses of glycopyrrolate, and were not accompanied by AV conduction disturbance as is frequently seen during a transient increase in vagal tone. "
08/01/2011 - "None of 34 patients administered glycopyrrolate and 6 of 35 (17%) patients receiving saline experienced bradycardia (P = 0.02476). "